Emami, A., Ebner, N., and von Haehling, S. (2017) Publishing in a heart failure journal---where lies the scientific interest?. ESC Heart Failure, 4: 389--401. doi: [10.1002/ehf2.12233](10.1002/ehf2.12233).

When you create a new journal, like *ESC Heart Failure*, people give you a rather lot of time for development of style and performance. Nowadays, it regularly takes 4--6 years to get recognized in PubMed and then another 1--2 years to obtain an impact factor. That is, when all is going reasonably well.

When you take over an established journal, like the *European Journal of Heart Failure*, people expect fast success or at least visible change. With regard to the look and feel of a journal, editorial style, and communication as well as editorial office performance, it is indeed possible for a new editor‐in‐chief to give a journal a new style fairly quickly. However, performance markers like the impact factor can only be impacted upon slowly.

Marco Metra has been the editor‐in‐chief of the *European Journal of Heart Failure* since the end of 2014 with responsibility for all published articles since January 2015. Only slowly can we fully appreciate the impact he has on the flagship journal of the Heart Failure Association of the European Society of Cardiology. And only the 2017 impact factor, which will come out in the summer of 2018, will then fully reflect his work and that of his team.

During the last summer, we learned about the 2016 impact factors. The *European Journal of Heart Failure* strongly recovered from a reduction in impact factor last year and now features an impact factor of 6.968, which is markedly higher than its 2015 impact factor of 5.135, or the 2014 and 2013 impact factors of 6.526 and 6.577, respectively. For external comparison, the 2016 impact factors of *JACC‐HF*, *Circulation Heart Failure*, and *Journal of Cardiac Failure* are 8.493, 6.372, and 4.983, respectively.

The 2016 impact factor of a journal of interest is based on the 2016 citations anywhere in the International Scientific Indexing recognized journals of papers published in 2014 and 2015 in that journal of interest divided by the number of full papers and reviews published in that journal that year. Journals can, to a small degree, modify the number of papers published. However, fewer papers published means in the future also fewer papers to cite, so the impact of publishing fewer papers is at best short term. Whether we like this or not, the impact factor is key for the external reputation of a journal, and the number of citations to its articles is also key. In order to fully understand what kind of research is cited, reading rakings of best‐cited articles can be helpful. In *Tables* [1](#ehf212233-tbl-0001){ref-type="table-wrap"}, [2](#ehf212233-tbl-0002){ref-type="table-wrap"}, and [3](#ehf212233-tbl-0003){ref-type="table-wrap"}, we list the 30 best‐cited articles of the *European Journal of Heart Failure* related to their respective year of publication; that is, 2014, 2015, and 2016. Of course, there is a time lag between publication and citation, and hence, it is not surprising that, on average, the articles of 2014 are somewhat more cited than those from 2015 or 2016. The 30th best‐cited article from 2014 was cited 24 times (*Table* [1](#ehf212233-tbl-0001){ref-type="table-wrap"}), that of 2015 was cited 20 times (*Table* [2](#ehf212233-tbl-0002){ref-type="table-wrap"}), and that of 2016 was cited only 11 times (*Table* [3](#ehf212233-tbl-0003){ref-type="table-wrap"}).

###### 

Top 30 cited articles, published in the *European Journal of Heart Failure* in 2014

  Rank   First author   Title                                                                                                                                                                                                                                                                    Times cited
  ------ -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------
  1      van Deursen    Co‐morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey[1](#ehf212233-bib-0001){ref-type="ref"}                                                                                                                            69
  2      Pieske         Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)[2](#ehf212233-bib-0002){ref-type="ref"}                                                                                                                             52
  3      Rogers         Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved[3](#ehf212233-bib-0003){ref-type="ref"}                                                                                                  49
  4      Gronda         Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof‐of‐concept study[4](#ehf212233-bib-0004){ref-type="ref"}                                                                    47
  5      McMurray       Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)[5](#ehf212233-bib-0005){ref-type="ref"}                                        47
  6      Lund           Association between cardiovascular vs. non‐cardiovascular co‐morbidities and outcomes in heart failure with preserved ejection fraction[6](#ehf212233-bib-0006){ref-type="ref"}                                                                                          46
  7      Huang          Uric acid and risk of heart failure: a systematic review and meta‐analysis[7](#ehf212233-bib-0007){ref-type="ref"}                                                                                                                                                       43
  8      Santos         Impaired left atrial function in heart failure with preserved ejection fraction[8](#ehf212233-bib-0008){ref-type="ref"}                                                                                                                                                  39
  9      Saberniak      Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members[9](#ehf212233-bib-0009){ref-type="ref"}                                                                  38
  10     Tarone         Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology[10](#ehf212233-bib-0010){ref-type="ref"}                                             37
  11     Mentz          Decongestion in acute heart failure[11](#ehf212233-bib-0011){ref-type="ref"}                                                                                                                                                                                             36
  12     Mentz          International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short‐term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial[12](#ehf212233-bib-0012){ref-type="ref"}              35
  13     Jhund          Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial[13](#ehf212233-bib-0013){ref-type="ref"}   32
  14     Brannstrom     Effects of person‐centred and integrated chronic heart failure and palliative home care. PREFER: a randomized controlled study[14](#ehf212233-bib-0014){ref-type="ref"}                                                                                                  31
  15     Lam            The middle child in heart failure: heart failure with mid‐range ejection fraction (40--50%)[15](#ehf212233-bib-0015){ref-type="ref"}                                                                                                                                     31
  16     Sliwa          EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM[16](#ehf212233-bib-0016){ref-type="ref"}                     31
  17     Pfister        Estimated urinary sodium excretion and risk of heart failure in men and women in the EPIC‐Norfolk study[17](#ehf212233-bib-0017){ref-type="ref"}                                                                                                                         29
  18     Clark          Worsening renal function during renin--angiotensin--aldosterone system inhibitor initiation and long‐term outcomes in patients with left ventricular systolic dysfunction[18](#ehf212233-bib-0018){ref-type="ref"}                                                       29
  19     Voors          Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome---an analysis from RELAX‐AHF[19](#ehf212233-bib-0019){ref-type="ref"}                                                                                         28
  20     Duncker        Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function---value of the wearable cardioverter/defibrillator[20](#ehf212233-bib-0020){ref-type="ref"}                                                               28
  21     Russo          Prevalence and prognostic value of subclinical left ventricular systolic dysfunction by global longitudinal strain in a community‐based cohort[21](#ehf212233-bib-0021){ref-type="ref"}                                                                                  28
  22     Fito           Effect of the Mediterranean diet on heart failure biomarkers: a randomized sample from the PREDIMED trial[22](#ehf212233-bib-0022){ref-type="ref"}                                                                                                                       28
  23     Nymo           Inflammatory cytokines in chronic heart failure: interleukin‐8 is associated with adverse outcome. Results from CORONA[23](#ehf212233-bib-0023){ref-type="ref"}                                                                                                          27
  24     Kang           Two‐dimensional speckle tracking echocardiography combined with high‐sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine‐based chemotherapy[24](#ehf212233-bib-0024){ref-type="ref"}                                     26
  25     Sondergaard    Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure[25](#ehf212233-bib-0025){ref-type="ref"}                                                                     25
  26     Cohen‐Solal    High prevalence of iron deficiency in patients with acute decompensated heart failure[26](#ehf212233-bib-0026){ref-type="ref"}                                                                                                                                           24
  27     Boehm          Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I‐Preserve)[27](#ehf212233-bib-0027){ref-type="ref"}                                                                    24
  28     De Ferrari     Rationale and study design of the NEuroCardiac TherApy foR Heart Failure Study: NECTAR‐HF[28](#ehf212233-bib-0028){ref-type="ref"}                                                                                                                                       24
  29     Merlo          Long‐term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years[29](#ehf212233-bib-0029){ref-type="ref"}                                                                             24
  30     Valente        The Chronic Kidney Disease Epidemiology Collaboration equation outperforms the Modification of Diet in Renal Disease equation for estimating glomerular filtration rate in chronic systolic heart failure[30](#ehf212233-bib-0030){ref-type="ref"}                       24

All data are as of 20 September 2017.

###### 

Top 30 cited articles, published in the *European Journal of Heart Failure* in 2015

  Rank   First author       Title                                                                                                                                                                                                                                                                                                                Times cited
  ------ ------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------
  1      Mebazaa            Recommendations on pre‐hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine[31](#ehf212233-bib-0031){ref-type="ref"}   85
  2      Watson             MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure[32](#ehf212233-bib-0032){ref-type="ref"}                                                                                                                                                                                    45
  3      Wong               Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction[33](#ehf212233-bib-0033){ref-type="ref"}                                                                                                                                                                        42
  4      Pitt               Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study‐Heart Failure (ARTS‐HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease[34](#ehf212233-bib-0034){ref-type="ref"}                  41
  5      Ferrari            Heart failure with preserved ejection fraction: uncertainties and dilemmas[35](#ehf212233-bib-0035){ref-type="ref"}                                                                                                                                                                                                  40
  6      Harjola            Clinical picture and risk prediction of short‐term mortality in cardiogenic shock[36](#ehf212233-bib-0036){ref-type="ref"}                                                                                                                                                                                           36
  7      Voors              Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction[37](#ehf212233-bib-0037){ref-type="ref"}                                                                                                                                        36
  8      McMurray           Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances[38](#ehf212233-bib-0038){ref-type="ref"}                                                                                                                                                                            35
  9      de Boer            State of the art: newer biomarkers in heart failure[39](#ehf212233-bib-0039){ref-type="ref"}                                                                                                                                                                                                                         33
  10     Edelmann           Galectin‐3 in patients with heart failure with preserved ejection fraction: results from the Aldo‐DHF trial[40](#ehf212233-bib-0040){ref-type="ref"}                                                                                                                                                                 33
  11     Shimokawa          Heart failure as a general pandemic in Asia[41](#ehf212233-bib-0041){ref-type="ref"}                                                                                                                                                                                                                                 31
  12     Bowen              Heart failure with preserved ejection fraction induces molecular, mitochondrial, histological, and functional alterations in rat respiratory and limb skeletal muscle[42](#ehf212233-bib-0042){ref-type="ref"}                                                                                                       31
  13     Rossignol          Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI‐HF and Val‐HeFT trials[43](#ehf212233-bib-0043){ref-type="ref"}                                                                                                                              30
  14     Kao                Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response[44](#ehf212233-bib-0044){ref-type="ref"}                                                                                                                    29
  15     Brunner‐La Rocca   Impact of worsening renal function related to medication in heart failure[45](#ehf212233-bib-0045){ref-type="ref"}                                                                                                                                                                                                   27
  16     Lip                Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation[46](#ehf212233-bib-0046){ref-type="ref"}                                                                                                                     26
  17     Felker             Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX‐AHF study[47](#ehf212233-bib-0047){ref-type="ref"}                                                                                                                                                            25
  18     Coiro              Prognostic value of residual pulmonary congestion at discharge assessed by lung ultrasound imaging in heart failure[48](#ehf212233-bib-0048){ref-type="ref"}                                                                                                                                                         25
  19     Akpek              Protective effects of spironolactone against anthracycline‐induced cardiomyopathy[49](#ehf212233-bib-0049){ref-type="ref"}                                                                                                                                                                                           25
  20     Sulaiman           Clinical characteristics, management, and outcomes of acute heart failure patients: observations from the Gulf acute heart failure registry (Gulf CARE)[50](#ehf212233-bib-0050){ref-type="ref"}                                                                                                                     23
  21     D\'Elia            Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use[51](#ehf212233-bib-0051){ref-type="ref"}                                                                                                                                 22
  22     Steinbeck          Detection of muscle wasting in patients with chronic heart failure using C‐terminal agrin fragment: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure (SICA‐HF)[52](#ehf212233-bib-0052){ref-type="ref"}                                                                               22
  23     Anker              Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trial[53](#ehf212233-bib-0053){ref-type="ref"}                                                                                              22
  24     Pitt               Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors[54](#ehf212233-bib-0054){ref-type="ref"}                                                                                                         22
  25     Larsson            Alcohol consumption and risk of heart failure: a dose--response meta‐analysis of prospective studies[55](#ehf212233-bib-0055){ref-type="ref"}                                                                                                                                                                        22
  26     Heymans            Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential[56](#ehf212233-bib-0056){ref-type="ref"}                                                                                                                                                                            21
  27     Piepoli            ExtraHF survey: the first European survey on implementation of exercise training in heart failure patients[57](#ehf212233-bib-0057){ref-type="ref"}                                                                                                                                                                  21
  28     Xiong              Non‐vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta‐analysis of randomized trials[58](#ehf212233-bib-0058){ref-type="ref"}                                                                                           20
  29     Gabet              National trends in rate of patients hospitalized for heart failure and heart failure mortality in France, 2000--2012[59](#ehf212233-bib-0059){ref-type="ref"}                                                                                                                                                        20
  30     McDonagh           Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?[60](#ehf212233-bib-0060){ref-type="ref"}                                                                                                                                                                            20

All data are as of 20 September 2017.

###### 

Top 30 cited articles, published in the *European Journal of Heart Failure* in 2016

  Rank   First author   Title                                                                                                                                                                                                                                                                                                                                                       Times cited
  ------ -------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------
  1      Ponikowski     2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[61](#ehf212233-bib-0061){ref-type="ref"}   318
  2      Lyon           Current state of knowledge on Takotsubo syndrome: a position statement from the task force on Takotsubo syndrome of the Heart Failure Association of the European Society of Cardiology[62](#ehf212233-bib-0062){ref-type="ref"}                                                                                                                            81
  3      van Riet       Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review[63](#ehf212233-bib-0063){ref-type="ref"}                                                                                                                                                                          32
  4      Vegter         MicroRNAs in heart failure: from biomarker to target for therapy[64](#ehf212233-bib-0064){ref-type="ref"}                                                                                                                                                                                                                                                   29
  5      ter Maaten     Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation[65](#ehf212233-bib-0065){ref-type="ref"}                                                                                                                                                                              28
  6      Crespo‐Leiro   European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions[66](#ehf212233-bib-0066){ref-type="ref"}                                                                                                                                                                              27
  7      Ovchinnikova   Signature of circulating microRNAs in patients with acute heart failure[67](#ehf212233-bib-0067){ref-type="ref"}                                                                                                                                                                                                                                            27
  8      Triposkiadis   Reframing the association and significance of co‐morbidities in heart failure[68](#ehf212233-bib-0068){ref-type="ref"}                                                                                                                                                                                                                                      24
  9      Jankowska      Effects of intravenous iron therapy in iron‐deficient patients with systolic heart failure: a meta‐analysis of randomized controlled trials[69](#ehf212233-bib-0069){ref-type="ref"}                                                                                                                                                                        23
  10     Aschauer       The right heart in heart failure with preserved ejection fraction: insights from cardiac magnetic resonance imaging and invasive haemodynamics[70](#ehf212233-bib-0070){ref-type="ref"}                                                                                                                                                                     23
  11     Vidan          Prevalence and prognostic impact of frailty and its components in non‐dependent elderly patients with heart failure[71](#ehf212233-bib-0071){ref-type="ref"}                                                                                                                                                                                                22
  12     Harjola        Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology[72](#ehf212233-bib-0072){ref-type="ref"}                                                                                     21
  13     Senni          Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens[73](#ehf212233-bib-0073){ref-type="ref"}                                                                                                                                                                 20
  14     Stiermaier     Long‐term excess mortality in Takotsubo cardiomyopathy: predictors, causes and clinical consequences[74](#ehf212233-bib-0074){ref-type="ref"}                                                                                                                                                                                                               19
  15     Demissei       Optimizing clinical use of biomarkers in high‐risk acute heart failure patients[75](#ehf212233-bib-0075){ref-type="ref"}                                                                                                                                                                                                                                    18
  16     Christ         Heart failure epidemiology 2000--2013: insights from the German Federal Health Monitoring System[76](#ehf212233-bib-0076){ref-type="ref"}                                                                                                                                                                                                                   17
  17     Unger          Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction[77](#ehf212233-bib-0077){ref-type="ref"}                                                                                                                                                          17
  18     Anker          Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency[78](#ehf212233-bib-0078){ref-type="ref"}                                                                                                                                                           16
  19     Schmidt        Thirty‐year trends in heart failure hospitalization and mortality rates and the prognostic impact of co‐morbidity: a Danish nationwide cohort study[79](#ehf212233-bib-0079){ref-type="ref"}                                                                                                                                                                15
  20     Mann           One‐year follow‐up results from AUGMENT‐HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure[80](#ehf212233-bib-0080){ref-type="ref"}                                                                                                                     15
  21     Bartunek       Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART‐1) trial design[81](#ehf212233-bib-0081){ref-type="ref"}                                                                                                                                                                                                                                 15
  22     Vardeny        Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial[82](#ehf212233-bib-0082){ref-type="ref"}                                                                                                                                                                   14
  23     Pearse         Sleep‐disordered breathing in heart failure[83](#ehf212233-bib-0083){ref-type="ref"}                                                                                                                                                                                                                                                                        14
  24     Komajda        Physicians\' adherence to guideline‐recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey[84](#ehf212233-bib-0084){ref-type="ref"}                                                                                                                                                                   12
  25     Maggioni       The real‐world evidence of heart failure: findings from 41 413 patients of the ARNO database[85](#ehf212233-bib-0085){ref-type="ref"}                                                                                                                                                                                                                       12
  26     Damman         Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction[86](#ehf212233-bib-0086){ref-type="ref"}                                                                                                                                                                                                   12
  27     Klersy         Effect of telemonitoring of cardiac implantable electronic devices on healthcare utilization: a meta‐analysis of randomized controlled trials in patients with heart failure[87](#ehf212233-bib-0087){ref-type="ref"}                                                                                                                                       12
  28     Chan           Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction[88](#ehf212233-bib-0088){ref-type="ref"}                                                                                                                                                                                                                     12
  29     Marques        The transcardiac gradient of cardio‐microRNAs in the failing heart[89](#ehf212233-bib-0089){ref-type="ref"}                                                                                                                                                                                                                                                 11
  30     Stugiewicz     The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications[90](#ehf212233-bib-0090){ref-type="ref"}                                                                                                                                                                                           11

All data are as of 20 September 2017.

Nevertheless, this is not the whole truth. Certain very topical reviews and, in particular, guidelines get cited way out of proportion. The best‐cited and second‐best‐cited articles from 2014 have so far been cited 69 and 52 times, respectively (*Table* [1](#ehf212233-tbl-0001){ref-type="table-wrap"}), and those of 2015 have so far been cited 85 and 45 times, respectively (*Table* [2](#ehf212233-tbl-0002){ref-type="table-wrap"}). In contrast, the best‐cited and second‐best‐cited articles published in the *European Journal of Heart Failure* in 2016 were cited 318 and 81 times, respectively (*Table* [3](#ehf212233-tbl-0003){ref-type="table-wrap"}). Not surprisingly, these articles are the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[61](#ehf212233-bib-0061){ref-type="ref"} and the position statement from the task force on Takotsubo syndrome of the Heart Failure Association.[62](#ehf212233-bib-0062){ref-type="ref"} Such articles provide guidance to a broad clinical community but often also form the basis of statements associated with many citations in the medical literature worldwide. To strengthen this point further, in *Table* [4](#ehf212233-tbl-0004){ref-type="table-wrap"}, we list the 50 best‐cited papers published in the *European Journal of Heart Failure*. The number of citations varies between 1131 (rank 1, 2008 *ESC Heart Failure* guideline[91](#ehf212233-bib-0091){ref-type="ref"}), 719 (rank 2, 2012 *ESC Heart Failure* guideline[92](#ehf212233-bib-0092){ref-type="ref"}), and 505 for the classical heart failure is more 'malignant' than cancer paper of Simon Stewart and colleagues (rank 3[93](#ehf212233-bib-0093){ref-type="ref"}) to a paper on serum levels of microRNA in heart failure patients published by Goren *et al*.[139](#ehf212233-bib-0139){ref-type="ref"} and cited 127 times so far (rank 50, see *Table* [4](#ehf212233-tbl-0004){ref-type="table-wrap"}). In the top 10 best‐cited papers published in the *European Journal of Heart Failure*, three are guidelines and four are big reviews. The next 10 best‐cited papers contain no guidelines, but others are five reviews, one meta‐analysis, and one trial design paper (*Table* [4](#ehf212233-tbl-0004){ref-type="table-wrap"}). If one does not consider biomarker papers on circulating levels of cardiac autoantibodies[129](#ehf212233-bib-0129){ref-type="ref"} or of microRNA[139](#ehf212233-bib-0139){ref-type="ref"} basic science---which we don\'t---then we need to conclude that not a single article of the top 50 cited papers in the *European Journal of Heart Failure* deals with basic science research. This may be considered a weakness of the journal, or simply a reality. The basic science community does not submit its best papers to this journal, which is considered to mostly serve a clinical readership.

###### 

Top 50 cited articles, ever published in the *European Journal of Heart Failure*

  Rank   First author      Title                                                                                                                                                                                                                                                                                                                                                                                                                  Times cited
  ------ ----------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------
  1      Dickstein         ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)[91](#ehf212233-bib-0091){ref-type="ref"}   1132
  2      McMurray          ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC[92](#ehf212233-bib-0092){ref-type="ref"}                                                                           719
  3      Stewart           More 'malignant' than cancer? Five‐year survival following a first admission for heart failure[93](#ehf212233-bib-0093){ref-type="ref"}                                                                                                                                                                                                                                                                                505
  4      Maisel            State of the art: using natriuretic peptide levels in clinical practice[94](#ehf212233-bib-0094){ref-type="ref"}                                                                                                                                                                                                                                                                                                       368
  5      Ponikowski        2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[61](#ehf212233-bib-0061){ref-type="ref"}                                                              318
  6      Oldenburg         Sleep‐disordered breathing in patients with symptomatic heart failure---a contemporary study of prevalence in and characteristics of 700 patients[95](#ehf212233-bib-0095){ref-type="ref"}                                                                                                                                                                                                                             298
  7      Stewart           The current cost of heart failure to the National Health Service in the UK[96](#ehf212233-bib-0096){ref-type="ref"}                                                                                                                                                                                                                                                                                                    297
  8      Hall              Essential biochemistry and physiology of (NT‐pro)BNP[97](#ehf212233-bib-0097){ref-type="ref"}                                                                                                                                                                                                                                                                                                                          249
  9      Sliwa             Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy[98](#ehf212233-bib-0098){ref-type="ref"}                                                                                                                            238
  10     Vogels            Cognitive impairment in heart failure: a systematic review of the literature[99](#ehf212233-bib-0099){ref-type="ref"}                                                                                                                                                                                                                                                                                                  230
  11     Cleland           The CARE‐HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end‐points[100](#ehf212233-bib-0100){ref-type="ref"}                                                                                                                                                                                                                                                                       208
  12     Berry             Economics of chronic heart failure[101](#ehf212233-bib-0101){ref-type="ref"}                                                                                                                                                                                                                                                                                                                                           205
  13     Lam               Epidemiology and clinical course of heart failure with preserved ejection fraction[102](#ehf212233-bib-0102){ref-type="ref"}                                                                                                                                                                                                                                                                                           201
  14     Gheorghiade       Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine[103](#ehf212233-bib-0103){ref-type="ref"}                                                                                                                199
  15     Metra             Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance[104](#ehf212233-bib-0104){ref-type="ref"}                                                                                                                                                                                                                                                 199
  16     Cleland           Clinical trials update from the American Heart Association: REPAIR‐AMI, ASTAMI, JELIS, MEGA, REVIVE‐II, SURVIVE, and PROACTIVE[105](#ehf212233-bib-0105){ref-type="ref"}                                                                                                                                                                                                                                               197
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We believe that the results of this short analysis are not surprising. They can make the working of the impact factor and the realities of publishing articles better understandable or even predictable. We believe that the *European Journal of Heart Failure* under the stewardship of Marco Metra is thriving, and we are most optimistic that the journal will grow further in the next few years in quality, readership, and reach, and likely also in impact factor.
